Thank you for Subscribing to CIO Applications Weekly Brief

Study Reveals That An Ai Model Can Help Optimize Ovulation Trigger Injection Timing To Improve Ivf Patient Outcomes
A study conducted by researchers at Alife Health, a fertility technology company that develops artificial intelligence (AI)
By
CIO Applications | Wednesday, June 01, 2022

Retrospective data suggest that over half of IVF cycles had potential early or late trigger injections, influencing egg retrieval outcomes.
Fremont, CA: A study conducted by researchers at Alife Health, a fertility technology company that develops artificial intelligence (AI) tools to improve IVF outcomes, discovered that an interpretable machine learning model could help doctors optimize ovulation trigger injection timing to enhance the quality of care for a significant number of patients.
Patients undergoing IVF are given fertility medicines to stimulate their ovaries into producing numerous eggs or oocytes. During this period, clinicians make key decisions that affect the cycle's result. One of the most critical considerations is when to administer the last trigger injection to stimulate oocyte maturation. Triggering too early may prevent the oocytes from maturing, while triggering too late may result in post-mature oocytes, reducing the odds of successful fertilization and generating viable embryos for IVF pregnancy.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The study, published online in Fertility & Sterility, is among the first to create an interpretable machine learning model to aid doctors in optimizing the day of the trigger during ovarian stimulation. The researchers used over 30,000 historical IVF cycles done at several institutions between 2014 and 2020 for their study, undertaken with colleagues from RMA New York, Boston IVF, RSC Bay Area, and UCSF.
According to the study's findings, Alife's machine learning model might assist clinicians in retrieving up to two to three more mature oocytes, two more fertilized oocytes, and one more useful blastocyst (embryo). In addition, the findings support previously published findings and do so across numerous clinics and with a significantly larger sample size. Nevertheless, the authors acknowledge the study's shortcomings; the most significant is its retrospective character.
More in News

